Physician profile
Benedict L Go
NPI 1831147768
$20,768.27
in general payments reported to CMS, 2019-2025
61 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,996 · 2020: $2,964 · 2021: $3,634 · 2022: $3,952 · 2023: $3,215 · 2024: $2,405 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,172 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,172.01 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,515.26 | 2020-2025 | |
| Lilly USA, LLC | $2,290.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $2,274.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,232.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $972.06 | 2019-2024 | Evenity, Prolia, Repatha |
| Pfizer INC. | $941.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.94 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $650.69 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $605.38 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $573.53 | 2019-2025 | Trintellix, Gattex |
| Currax Pharmaceuticals LLC | $539.98 | 2020-2025 | Contrave, Nexletol, Nexlizet |
| Mylan Specialty L.P. | $537.95 | 2020-2024 | Yupelri |
| Allergan, INC. | $512.11 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $471.16 | 2021-2023 | |
| Axsome Therapeutics, INC. | $435.97 | 2023-2025 | Symbravo, Sunosi, Auvelity |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.